Page 2 - Shimadzu Journal vol.9 Issue2

Note from the Director

Yoshiaki Mase
General Manager,
Analytical & Measurement Instruments Division

As “a company that solves challenges in society in (APHP) talked about the results of research related to
collaboration with partners all around the world”, improvements in pharmaceutical management (per-
Shimadzu Corporation aims to create and promote sonalized medicine), in the context of a project to test
solutions to these challenges. Even as the impacts from and evaluate the pharmacokinetics of monoclonal an-
the COVID-19 pandemic still continue, Shimadzu’s tibodies addressed through collaborative research with
Infectious Disease Countermeasure Projects, which Shimadzu.
were established in 2020 as important emergency In addition to these interviews, we introduce exam-
challenges, entered a new stage, Phase II, in 2021. We ples of the analysis of antibody drugs using our new
actively engage in creating new methods, networks UHPLC, Nexera XS inert, applications analyzed with
and systems. Fields and approaches related to analyti- HPLC, LC-MS/MS, and FTIR, and the results of research
cal and measuring instruments are changing, as the from collaborations using nSMOL(nano-surface and
movement of people and things changes worldwide, molecular-orientation limited proteolysis). We also in-
and business activities and working practices change troduce the latest initiatives by Shimadzu related to
rapidly in various countries and regions. biopharmaceuticals.

In the midst of such large changes across the whole of Further social changes are likely to continue into the
society of the world, this issue features biopharma- future. Yet Shimadzu is realizing its corporate philoso-
ceuticals, which are rapidly increasing in presence at phy of “Contributing to Society through Science and
the worldwide. We introduce the researchers active Technology,” so as to embrace change rather than
on the front lines of biopharmaceutical research, as fearing it, and to create an even better society. While
well as the applications making use of cutting-edge working cooperatively with you in the cutting-edge
technology related to the biopharmaceutical field. and innovative research and challenging activities in
To begin with, we talked with Ms. Shraddha Mane, which you are engaged, we hope to stimulate your
head of quality control at HiMedia Laboratories Pvt Ltd. work through this journal.
about the development of cell culture media and re-
lated analysis systems. Next, we heard from Dr. Shivam Yours Sincerely,
Mukherjee of Intas Pharmaceuticals Ltd. He talked
about the importance of cell culture conditions in the
development of therapeutic monoclonal antibody bio-
similars and about cell culture profiling. In addition, Dr.
Noel Zahr of Assistance Publique–Hôpitauxde Paris

Shimadzu Journal vol.9 Issue2 35